CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
// Faheem Ahmed Khan 1 , Nuruliarizki Shinta Pandupuspitasari 1 , Huang Chun-Jie 1 , Zhou Ao 1 , Muhammad Jamal 2 , Ali Zohaib 3 , Farhan Ahmed Khan 4 , Muthia Raihana Hakim 5 and Zhang ShuJun 1 1 Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Education Ministry of China, Huazhong Agricultural University, Wuhan, People’s Republic of China 2 State Key Laboratory of Agriculture Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China 3 Key Laboratory of Special Pathogens and Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China 4 Department of Cardiovascular Medicine, Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences, Islamabad, Pakistan 5 Tongji Medical College, Huazhong University of Science And Technology, Wuhan, China Correspondence to: Zhang ShuJun, email: // Keywords : CRISPR/Cas9, genetic diseases, cancer, genome editing, next generation sequencing Received : March 12, 2016 Accepted : May 19, 2016 Published : May 26, 2016 Abstract Cancer is caused by a series of alterations in genome and epigenome mostly resulting in activation of oncogenes or inactivation of cancer suppressor genes. Genetic engineering has become pivotal in the treatment of cancer and other genetic diseases, especially the formerly-niche use of clustered regularly interspaced short palindromic repeats (CRISPR) associated with Cas9. In defining its superior use, we have followed the recent advances that have been made in producing CRISPR/Cas9 as a therapy of choice. We also provide important genetic mutations where CRISPRs can be repurposed to create adaptive immunity to fight carcinomas and edit genetic mutations causing it. Meanwhile, challenges to CRISPR technology are also discussed with emphasis on ability of pathogens to evolve against CRISPRs. We follow the recent developments on the function of CRISPRs with different carriers which can efficiently deliver it to target cells; furthermore, analogous technologies are also discussed along CRISPRs, including zinc-finger nuclease (ZFN) and transcription activator-like effector nucleases (TALENs). Moreover, progress in clinical applications of CRISPR therapeutics is reviewed; in effect, patients can have lower morbidity and/or mortality from the therapeutic method with least possible side-effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“These methods involve electroporation [48], microinjection [49, 50] lipofection [51, 52] nucleofection [51-53].”
MethodThe complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones
Cech, T. R., & Steitz, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.008 · Cited by 2,524
Crystal structure of Cas9 in complex with guide RNA and target DNA
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014) · Cell · doi:10.1016/j.cell.2014.02.001 · Cited by 2,306 · cited 1×
“The RNA guided DNA breaks is elucidated by understanding the crystal structure of SpCas9 and constructing the truncated Cas9 mutant that facilitates its in vivo therapeutic application by providing a mechanism of its packaging in size restraint viral vectors [33].”
BackgroundKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“The in vivo delivery of nucleases is addressed by Zuris and colleagues, they conclusively show that proteins delivery by cationic lipid is a viable approach for genome editing and is capable of carrying Cre recombinase, TALE, CRISPR/Cas9: gRNA and Cas9 transcription factor activators [57] (Figure 2).”
BackgroundMaruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Cited by
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229
Nakagawara, A., Li, Y., Izumi, H., Muramori, K., Inada, H., & Nishi, M. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx176 · Cited by 197
De Masi, C., Spitalieri, P., Murdocca, M., Novelli, G., & Sangiuolo, F. (2020) · Human Genomics · doi:10.1186/s40246-020-00276-2 · Cited by 91
Takao, A., Yoshikawa, K., Karnan, S., Ota, A., Uemura, H., De Velasco, M., Kura, Y., Suzuki, S., Ueda, R., Nishino, T., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6683 · Cited by 26
Metadata
- Authors
- Khan, F. A., Pandupuspitasari, N. S., Chun-Jie, H., Ao, Z., Jamal, M., Zohaib, A., Khan, F. A., Hakim, M. R., & ShuJun, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-05-26
- Volume
- 7
- Issue
- 32
- Pages
- 52541-52552
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2408079107
- Cited by
- 111
- References
- 21
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.